Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
BerGenBio ASA ( (BRRGF) ) just unveiled an announcement.
Oncoinvent ASA has announced the details of a fully underwritten rights issue to raise NOK 130 million, with a subscription price set at NOK 0.50 per share, representing a 35% discount to the theoretical share price. This move requires a share capital reduction to be approved in an extraordinary general meeting, reflecting the company’s strategic financial adjustments to support its ongoing operations and development programs.
The most recent analyst rating on (BRRGF) stock is a Buy with a NOK38.00 price target. To see the full list of analyst forecasts on BerGenBio ASA stock, see the BRRGF Stock Forecast page.
More about BerGenBio ASA
Oncoinvent is a clinical-stage biotechnology company focused on developing novel radiopharmaceutical therapies against cancer. Their lead product, Radspherin®, targets micro-metastases in the peritoneum post-surgery using radium-224, and is currently undergoing clinical trials in the US and Europe.
Average Trading Volume: 110,225
Current Market Cap: NOK190.2M
Find detailed analytics on BRRGF stock on TipRanks’ Stock Analysis page.